Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Oruka Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −1 vs. Q2 2023
- Shares held
- 3.26M
- +459.6K (+16.4%) vs. Q2 2023
- Total value
- $6.55M
- +$867.5K (+15.3%) vs. Q2 2023
- New holders
- 3
- 4 more added
- Sold out
- 4
- 7 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ORKA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 255 | $7.05B |
| Q1 2026 | 184 | $2.55B |
| Q4 2025 | 143 | $1.60B |
| Q3 2025 | 105 | $875.8M |
| Q2 2025 | 81 | $386.0M |
| Q1 2025 | 71 | $326.1M |
| Q4 2024 | 66 | $606.6M |
| Q3 2024 | 42 | $604.2M |
| Q2 2024 | 32 | $49.4M |
| Q1 2024 | 23 | $12.7M |
| Q4 2023 | 25 | $12.7M |
| Q3 2023 | 21 | $6.55M |
| Q2 2023 | 23 | $5.75M |
| Q1 2023 | 26 | $5.02M |
| Q4 2022 | 22 | $6.19M |
| Q3 2022 | 25 | $4.58M |
| Q2 2022 | 24 | $4.17M |
| Q1 2022 | 22 | $2.60M |
| Q4 2021 | 21 | $2.41M |
| Q3 2021 | 19 | $4.53M |
| Q2 2021 | 17 | $4.16M |
| Q1 2021 | 17 | $3.20M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Oruka Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Western Standard LLC | 1,174,270 | $2.36M | 2.13% | +544,079+86.3% | Added |
| BML Capital Management, LLC | 706,930 | $1.42M | 1.31% | 00.0% | Unchanged |
| Vanguard Group Inc | 450,535 | $905.6K | 0.00% | −11,078−2.4% | Reduced |
| Newtyn Management, LLC | 300,000 | $603.0K | 0.15% | −13,200−4.2% | Reduced |
| BlackRock Inc. | 231,959 | $466.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 142,349 | $286.2K | 0.00% | −13,286−8.5% | Reduced |
| State Street Corp | 71,137 | $143.0K | 0.00% | −500−0.7% | Reduced |
| Renaissance Technologies LLC | 50,800 | $102.0K | 0.00% | +6,300+14.2% | Added |
| Bridgeway Capital Management, LLC | 46,948 | $94.4K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 42,514 | $85.5K | 0.00% | +120.0% | Added |
| Northern Trust Corp | 20,982 | $42.2K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 14,988 | $30.1K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,691 | $7.42K | 0.00% | +1,249+51.1% | Added |
| Parallel Advisors, LLC | 244 | $490 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 125 | $251 | 0.00% | +125 | New |
| Wells Fargo & Company | 75 | $151 | 0.00% | −29−27.9% | Reduced |
| Advisor Group Holdings, Inc. | 55 | $110 | 0.00% | −2−3.5% | Reduced |
| Qube Research & Technologies Ltd | 50 | $101 | 0.00% | +50 | New |
| Bank of America Corp | 31 | $62 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 12 | $24 | 0.00% | +12 | New |
| Royal Bank of Canada | 63 | $0 | 0.00% | −195−75.6% | Reduced |
| Murchinson Ltd. | 0 | $0 | 0.00% | −50,593−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,541−100.0% | Sold out |
| TD Waterhouse Canada Inc. | 0 | $0 | 0.00% | −1,300−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Tekla Capital Management LLC | – | – | – | – | Not filed |